1000minds
1 of 2 Introduction
2 of 2 Trade-offs: Q0

Patient drug treatment preferences for Raynaud’s phenomenon in systemic sclerosis ('scleroderma')

Painful attacks of Raynaud’s phenomenon occur in almost all patients with systemic sclerosis, often referred to as 'scleroderma'.

Although we have a wide range of drug therapies for Raynaud's readily available (and often relatively inexpensive), benefit varies between patients. Many patients also may experience side effects (e.g., headache, nausea, light-headiness), which can range from mild to severe.

Our aim is to understand patient decision-making; that is, how people living with scleroderma balance the benefit and safety of drug treatments used for Raynaud's phenomenon.

We invite you to complete our survey – a “discrete choice experiment” (DCE) – investigating how patients choose treatments for Raynaud's phenomenon.

This survey should take around 10-15 minutes (or less) and is completely anonymous and confidential.

You need be age 18 years or older AND have a confirmed clinical diagnosis of systemic sclerosis/scleroderma with Raynaud's phenomenon to take part in this current study.

After a few questions about your socio-demographic and background characteristics, you will be presented with approximately 40-50 pairs of scenarios related to hypothetical treatment options and asked to choose between them. Please don’t agonise too much, as there are no “correct” answers – we are interested in your personal preferences!

Please take the time to carefully read the study Patient Information Sheet:

PATIENT INFORMATION SHEET

For any issues, please contact: Michael.hughes-6@manchester.ac.uk

Many thanks in advance for your time and collaboration!

Yours Sincerely, Dr Michael Hughes (Manchester, UK) and Prof Dinesh Khanna (Michigan, USA)

Preparing your survey…

  • Export chart